ANPDFJul 171 min readAzafaros Media Release | July 16, 2024Azafaros announces positive topline Phase 2 study data with nizubaglustat in GM2 gangliosidosis and Niemann-Pick disease type C Read the...
ANPDFMar 141 min readAzafaros Media Release | March 12, 2024Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients.
ANPDFDec 21, 20231 min readAzafaros Media Release | December 11, 2023Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustat in GM2 and NPC patients, is now fully enrolled Read the full statement from...
ANPDFJan 10, 20231 min readAzafaros Media Releases | January 5-9, 2023"Azafaros Receives FDA's IND Clearance and Fast Track Designation for Lead Asset AZ-3102" Read the press release from January 5, 2023...
